Can bone turnover markers help to define the duration of biphosphonate drug holidays? by Statham, Louise et al.
Statham, Louise, Aspray, T. and Abdy, S. (2016) Can bone turnover markers help 
to define the duration of biphosphonate drug holidays? In: 43rd Annual European 
Calcified Tissue Society, 15 May 2016, Rome, Italy. 
Downloaded from: http://sure.sunderland.ac.uk/6354/
Usage guidelines
Please  refer  to  the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
Review (32%)
• Adherence
• Renal	function
• Recent	fracture
• Absorption
Consider	
restart
(28%)
Delay	
restart
(72%)
N	
Consider	
restart
(53%)
Delay	
restart
(47%)
At	Baseline	
CTX	≤	pre-menopausal	
mean*	
(68%)
4	month	Review	
CTX	supressed?
(i.e.	≤	mean	or	
LSC	not	achieved)	
12	month	Review
CTX	supressed?
(i.e.	≤	mean	or	
LSC	not	achieved)	
N	 N	
Total	Patients	=158	
• Patients on BP drug holiday via outpatient Bone Clinic identified from monitoring
records
• Data extracted; patient age, sex, serum CTX levels 0, 4, 12 months, bisphosphonate and
duration of use
• Excluded if baseline (0m) CTX ≥0.51 ug/L (higher fracture risk)
• Data analysis using Stata Statistics software.
• Offset of action defined as
• a rise by the Least Significant Change (LSC=33%*) in CTX and CTX above the
pre-menopausal mean (0.19ug/L)
*LSC=2.33x√(CVa2)+(CVi2): CVa is analytical coefficient of variation, CVi is intra-individual CV
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Figure	4:	CTX	monitoring	outcomes
at	baseline,	4	and	12	months
*Mean	premenopausal	CTX	0.19	ug/L(0.05-0.63)4
Figure 1: All patient characteristics
• After	at	least	5	years	of	treatment,	CTX	may	not	be	adequately	suppressed	in	a	third	of	
patients.	Drug	adherence	and	therapy	choice	should	be	reviewed	in	this	group.	
• Less	significant	changes	in	CTX	seen	if	levels	not	adequately	suppressed	at	baseline																		
?adherence
• Treatment	effects	can	wear	off	as	quickly	as	4	months,	but	may	also	be	maintained	for	12	
months
• Monitoring	of	CTX	can	potentially	be	used	to	identify	these	patients,	some	of	whom	may	
need	to	re-start	treatment	earlier
Mean Patient	Age 71	years
Gender 83%	female;	17%	male
Mean	Duration	BP 8	years	(range 3-15	years)
Alendronicacid 59%
Risedronate 33%
Other	
Bisphosphonate
8%
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BPs	impair	Bone	Turnover;	CTX	bone	turnover	marker	(bone	resorption)
• Start	BP	→	↓CTX
• Stop	BP	&	CTX	rises2
Local	practice	since	late	2012
• Review	BP	after	5	yrs
• Drug	holiday
• Routine	monitoring	CTX	at	baseline,	4	months	and	12	months
Our	aim	was	to	analyse	changes	in	CTX	on	stopping	long	term	bisphosphonate	treatment	
to	guide	clinical	decision-making	on	the	duration	of	treatment	cessation
Potential	for	harm
• Atypical	fractures,	osteonecrosis	of	the	jaw	(ONJ)
• Rare	occurrence,	↑risk	with	increasing	duration3
Good	evidence	for	5	years	bisphosphonate	(BP)	treatment1,2 but	beyond	this	less	clear	
• BP	long	half-life;	stopping	treatment	→	wears	off	gradually2
Drug	holidays increasingly	common	- stop	BP	for	period	of	time
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Figure	3:	CTX	at	0,	4,	12	months	for	defined	populations
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Significant	rise	(>LSC) 47% 69%
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Key:
Figure	2:	CTX	at	0,	4,	12	months	all	patients	
(<0.51	at	baseline)
a)	*0-4m	mean	CTX	+	0.05ug/L	(95%	CI	0.04-0.06)		
**0-12m	mean	CTX	+0.09ug/L	(95%	CI	0.07-0.10)
b)	*0-4m	mean	CTX	+	0.01ug/L	(95%	CI	-0.01-0.04)		
**0-12m	mean	CTX	+0.05ug/L	(95%	CI	0.01-0.09)
Overall	population	(figure	2):	
•Detectable	rise	in	CTX		seen	from	as	early	as	4	
months	in	47%	patients;	69%	at	12	months	
Subpopulations	(figure	3):
•If	CTX	≤	pre-menopausal	mean	(i.e.	treatment	
target)		at	baseline,		statistically	significant	
increases	in	CTX	seen	at	4	and	12	months
•If	CTX	>	pre-menopausal	mean	at	baseline,	no	
significant	change	at	4	months,	significant	by	12	
months
•No	significant	difference	between	Alendronic	acid	
and	Risedronate	seen	(data	not	shown)
Monitoring	outcomes	using	population	data	
(figure	4):
•Baseline	CTX	not	suppressed	to	premenopausal	
mean	level	after	5	yrs	of	BP	use	in	32%	patients
•Where	CTX	suppressed	at	baseline:
-At	4	months	28%	had	significant	rise	in	
CTX		that	was	also	above	mean	level	
(?consider	re-start)
-At	12	months	this	had	risen	to	53%;		
47%	CTX	still	suppressed	at	this	stage
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